Clinical trials: Sunitinib
Gastrointestinal Stromal Tumors
Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT
The objective of this study is to compare the clinical outcomes following resumption of dosing (re-challenge) with Imatinib plus best supportive care versus placebo plus best supportive care in patients with advanced/incurable…
- Trial name
- NCT01151852
- Testing
- Imatinib
- Where
- South Korea
- Volunteers
- 81 people
- Sponsor
- Asan Medical Center
Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors
Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors
The purpose of this expanded access program (EAP) is to provide investigational bezuclastinib so that it can be coadministered with sunitinib to patients with a diagnosis of gastrointestinal stromal tumors (GIST) with no…
- Trial name
- NCT06948955
- Testing
- Bezuclastinib, Sunitinib
- Where
- 26 sites in United States
- Sponsor
- Cogent Biosciences, Inc.
Carcinoma, Hepatocellular
Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer
The study will evaluate the efficacy and safety of sunitinib (Arm A), given at 37.5 mg orally once daily, compared to sorafenib (Arm B), given orally at 400 mg twice daily, in patients with inoperable liver cancer.
- Trial name
- NCT00699374
- Testing
- sunitinib malate, sorafenib
- Where
- 171 sites in United States, Australia and 21 more
- Volunteers
- 1,075 people
- Sponsor
- Pfizer
Carcinoma, Renal Cell
Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing
The purpose of this study is to determine the effect of a sunitinib administration schedule 2/1 (2 weeks of treatment followed by 1 week without) compared to a schedule 4/2 (4 weeks of treatment followed by 2 weeks without) on…
- Trial name
- ASSET (NCT03109015)
- Testing
- Sunitinib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Duke University
Metastatic Gastrointestinal Stromal Tumor
Ph II CABOGIST in GIST
The study is a multi-center, multi-national, open label, single arm Phase II study of single-agent cabozantinib. The objective of the study is to assess the safety and activity of cabozantinib in patients with metastatic GIST who…
- Trial name
- NCT02216578
- Testing
- cabozantinib
- Where
- 11 sites in Belgium, Czechia and 4 more
- Volunteers
- 51 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Cancer, Thyroid Carcinoma
Thyroid Cancer and Sunitinib
Due to arguments showing that angiogenesis could be involved in progression of metastatic thyroid carcinoma and to objective response during previous studies with sunitinib (an angiogenic oncology drug also known as Sutent), this…
- Trial name
- THYSU (NCT00510640)
- Testing
- Sunitinib
- Where
- 15 sites in France
- Volunteers
- 71 people
- Sponsor
- University Hospital, Bordeaux
Neuroendocrine Tumors, Pancreatic Neoplasms
A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
The purpose of this study is to determine the safety and the efficacy of the combination of the drugs TH-302 and sunitinib in metastatic neuroendocrine tumours.
- Trial name
- NCT02402062
- Testing
- TH-302 + Sunitinib
- Where
- 10 sites in Spain
- Volunteers
- 17 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Acute Myeloid Leukemia
Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years
In this study safety and tolerability of two dose levels of SU 11248 (sutent) with standard chemotherapy in patients with FLT3 mutated AML over 60 years will be evaluated.
- Trial name
- NCT00783653
- Testing
- Sunitinib
- Where
- 5 sites in Germany
- Volunteers
- 22 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Pancreatic Neuroendocrine Tumour Metastatic
Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to Sunitinib
The therapeutic goals in the management of pancreatic neuroendocrine tumors (pNET) are the control of symptoms and tumor growth control in order to improve patient survival.
- Trial name
- RESUNET (NCT02713763)
- Testing
- Sunitinib
- Where
- 9 sites in Spain
- Volunteers
- 11 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Clear Cell, Metastatic Renal Cell Carcinoma
Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule
This prospective single arm study will evaluate the efficacy and safety of sunitinib given on an individualized dosing schedule as first-line therapy in subjects with metastatic clear cell renal cell cancer.
- Trial name
- NCT01499121
- Testing
- Sunitinib
- Where
- 13 sites in Canada
- Volunteers
- 117 people
- Sponsor
- Sunnybrook Health Sciences Centre
Carcinoma, Renal Cell
Cardiovascular and Torsades de Pointes Monitoring for Pazopanib
This observational study is conducted as part of a systematic pharmacovigilance activity, to provide a population-based context for Pazopanib use outside of the clinical trial setting.
- Trial name
- NCT01446224
- Testing
- Pazopanib, Other anti-VEGFs
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Advanced or Metastatic Renal Cell Carcinoma, Renal Cancer
Study In Patients With Kidney Cancer Treated With Sutent
Objective of this study is to increase knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib.
- Trial name
- NCT00873210
- Testing
- Sutent
- Where
- 14 sites in Slovakia
- Volunteers
- 121 people
- Sponsor
- Pfizer
Renal Cell Carcinoma
A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)
This multi-center, randomized, open-label study will evaluate the efficacy and safety of atezolizumab plus bevacizumab versus sunitinib in participants with inoperable, locally advanced, or metastatic RCC who have not received…
- Trial name
- IMmotion151 (NCT02420821)
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Bevacizumab, Sunitinib
- Where
- 154 sites in United States, Australia and 19 more
- Volunteers
- 915 people
- Sponsor
- Hoffmann-La Roche
Metastatic Renal Cell Carcinoma
Phase II Study of Alternating Sunitinib and Temsirolimus
In the past 5 years, treatment for metastatic Renal Cell Carcinoma (mRCC) has focused on agents directed at blocking tumor and vascular growth pathways.
- Trial name
- NCT01517243
- Testing
- Sunitinib, Temsirolimus
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Gastrointestinal Stromal Tumor
Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST
The purpose of this research study is to determine the safety and tolerability of sunitinib alternating with regorafenib in participants with advanced gastrointestinal stromal tumor GIST, if the standard approved therapies…
- Trial name
- SURE (NCT02164240)
- Testing
- Sunitinib, Regorafenib
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Dana-Farber Cancer Institute
Well-differentiated Pancreatic Neuroendocrine Tumor
A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
The purpose of this study is to confirm the safety and efficacy of sunitinib in subjects with unresectable pancreatic neuroendocrine tumors.
- Trial name
- NCT01525550
- Testing
- sunitinib
- Where
- 26 sites in United States, Australia and 13 more
- Volunteers
- 106 people
- Sponsor
- Pfizer
Ovarian Cancer, Fallopian Tube Cancer
Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma
The purpose of this study is to determine the effectiveness of sunitinib on participants with ovarian, fallopian tube or peritoneal cancer.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT00768144
- Testing
- Sunitinib
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Dana-Farber Cancer Institute
Carcinoma, Renal Cell, Advanced, Lymphoma, Mantle-Cell
Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]
The purpose of this registry is to obtain a general view as regards efficacy, tolerability and safety issues of the Torisel®, Sutent®, and/or Inlyta® therapies in patients with advanced renal cell carcinoma, recurrent /…
- Conditions
- Carcinoma, Renal Cell, Advanced, Lymphoma, Mantle-Cell, Gastrointestinal Stroma Tumors
- Trial name
- STAR-TOR (NCT00700258)
- Testing
- Temsirolimus, Sunitinib, Axitinib
- Where
- 77 sites in Germany
- Volunteers
- 1,520 people
- Sponsor
- Pfizer
Metastatic Colorectal Cancer
Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer
The purpose of the study is to evaluate the safety and efficacy of FOLFIRI (Irinotecan, Leucovorin and 5 Fluorouracil) chemotherapy when combined with sunitinib or FOLFIRI chemotherapy without adding sunitinib as the first line…
- Trial name
- NCT00457691
- Testing
- 5 fluorouracil, irinotecan, levo- leucovorin
- Where
- 132 sites in Argentina, Australia and 32 more
- Volunteers
- 768 people
- Sponsor
- Pfizer
Malignant Solid Tumour
Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors
The purpose of this prospective study is to determine the safety and feasibility of pharmacokinetically (PK) guided dosing of sunitinib in 30 patients.
- Trial name
- NCT01286896
- Testing
- Sunitinib
- Where
- Netherlands
- Volunteers
- 43 people
- Sponsor
- The Netherlands Cancer Institute